Pesquisa | Portal de Pesquisa da BVS

1.

Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.

Crawford, E David; Hafron, Jason M; Debruyne, Frans; Wallis, Christopher; Chang, Steven; Garnick, Marc B.

J Urol ; 211(1): 63-70, 2024 Jan.

Artigo em Inglês | MEDLINE | ID: mdl-37796473

2.

Optimizing outcomes in men with prostate cancer: the cardiovascular event lowering (CaELo) pathways.

Crawford, David E; Albala, David; Garnick, Marc B; Hahn, Andrew W; Maroni, Paul; McKay, Rana R; Miner, Martin; Orio â¢, Peter; Pandit, Kshitij; Sellinger, Scott; Yu, Evan Y; Eckel, Robert H.

Can J Urol ; 31(2): 11820-11825, 2024 Apr.

Artigo em Inglês | MEDLINE | ID: mdl-38642459

3.

Reply: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.

Garnick, Marc B; Hafron, Jason; Crawford, E David.

J Urol ; 211(3): 482, 2024 Mar.

Artigo em Inglês | MEDLINE | ID: mdl-38179977

4.

More on Long-Term Effects of Finasteride on Prostate Cancer Mortality.

Garnick, Marc B.

N Engl J Med ; 380(20): e38, 2019 05 16.

Artigo em Inglês | MEDLINE | ID: mdl-31091399

5.

A Proposal for the Comprehensive Care of Men on Androgen Deprivation Therapy: Recommendations From the Multidisciplinary Prostate Cancer 360 Working Group.

Crawford, E David; Garnick, Marc B; Eckel, Robert H; Miner, Martin M; Freedland, Stephen J; Pachynski, Russell K; Wassersug, Richard J; Rosenberg, Matthew T; Walker, Lauren M; Fairman, Ciaran; Curley, Tracy; Crosby, Michael; Lin, Pao-Hwa; Hafron, Jason M.

Urol Pract ; 11(1): 18-29, 2024 01.

Artigo em Inglês | MEDLINE | ID: mdl-37917591

6.

The utility of prostate-specific antigen in the management of advanced prostate cancer.

Crawford, E David; Bennett, Charles L; Andriole, Gerald L; Garnick, Marc B; Petrylak, Daniel P.

BJU Int ; 112(5): 548-60, 2013 Sep.

Artigo em Inglês | MEDLINE | ID: mdl-23826876

7.

Filling in the Gaps.

Garnick, Marc B.

JAMA ; 319(20): 2079-2080, 2018 May 22.

Artigo em Inglês | MEDLINE | ID: mdl-29800185

8.

New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.

Garnick, Marc B; Mottet, Nicolas.

BJU Int ; 110(4): 499-504, 2012 Aug.

Artigo em Inglês | MEDLINE | ID: mdl-22093775

9.

Possible confusion in names of new treatments for prostate cancer.

Garnick, Marc B.

N Engl J Med ; 368(2): 194, 2013 Jan 10.

Artigo em Inglês | MEDLINE | ID: mdl-23301754

10.

More on confusion of drug names.

Garnick, Marc B.

N Engl J Med ; 368(20): 1947, 2013 05 16.

Artigo em Inglês | MEDLINE | ID: mdl-23675669

11.

Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.

San Francisco, Ignacio F; Werner, Lillian; Regan, Meredith M; Garnick, Marc B; Bubley, Glenn; DeWolf, William C.

J Urol ; 185(2): 471-6, 2011 Feb.

Artigo em Inglês | MEDLINE | ID: mdl-21167525

12.

Rethinking the use of physicians as hired expert lecturers.

Garnick, Marc B; Balter, Wendy.

Ann Intern Med ; 162(4): 320-1, 2015 Feb 17.

Artigo em Inglês | MEDLINE | ID: mdl-25686175

13.

Testosterone replacement therapy faces FDA scrutiny.

Garnick, Marc B.

JAMA ; 313(6): 563-4, 2015 Feb 10.

Artigo em Inglês | MEDLINE | ID: mdl-25502018

14.

Editorial Comment.

Garnick, Marc B; Crawford, E David.

Urol Pract ; 11(1): 161-162, 2024 01.

Artigo em Inglês | MEDLINE | ID: mdl-38117961

15.

Reply by Authors.

Crawford, E David; Garnick, Marc B; Eckel, Robert H; Miner, Martin M; Freedland, Stephen J; Pachynski, Russell K; Wassersug, Richard J; Rosenberg, Matthew T; Walker, Lauren M; Fairman, Ciaran; Curley, Tracy; Crosby, Michael; Lin, Pao-Hwa; Hafron, Jason M.

Urol Pract ; 11(1): 30-31, 2024 01.

Artigo em Inglês | MEDLINE | ID: mdl-38051218

16.

Editorial comment. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Garnick, Marc B.

BJU Int ; 110(8): 1155, 2012 Oct.

Artigo em Inglês | MEDLINE | ID: mdl-22369480

17.

The great prostate cancer debate.

Garnick, Marc B.

Sci Am ; 306(2): 38-43, 2012 Feb.

Artigo em Inglês | MEDLINE | ID: mdl-22295676

18.

Recommendations on use of prostate-specific antigen for prostate cancer screening.

Garnick, Marc B.

JAMA ; 307(13): 1372; author reply 1372-4, 2012 Apr 04.

Artigo em Inglês | MEDLINE | ID: mdl-22474197

19.

Ask the doctor. I take Avodart for my enlarged prostate. But I heard that Avodart increases prostate cancer risk. Is that true? Should I quit taking Avodart?

Garnick, Marc B.

Harv Health Lett ; 37(3): 8, 2012 Jan.

Artigo em Inglês | MEDLINE | ID: mdl-22400165

20.

EDITORIAL COMMENT.

Garnick, Marc B; Wagner, Andrew A.

Urology ; 165: 235, 2022 07.

Artigo em Inglês | MEDLINE | ID: mdl-35843696

Portal de Pesquisa da BVS

Informação e Conhecimento para a Saúde

Configurar filtros

Sua seleção (0)

Formato de exportação:

Exportar:

Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.

Optimizing outcomes in men with prostate cancer: the cardiovascular event lowering (CaELo) pathways.

Reply: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.

More on Long-Term Effects of Finasteride on Prostate Cancer Mortality.

A Proposal for the Comprehensive Care of Men on Androgen Deprivation Therapy: Recommendations From the Multidisciplinary Prostate Cancer 360 Working Group.

The utility of prostate-specific antigen in the management of advanced prostate cancer.

Filling in the Gaps.

New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.

Possible confusion in names of new treatments for prostate cancer.

More on confusion of drug names.

Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.

Rethinking the use of physicians as hired expert lecturers.

Testosterone replacement therapy faces FDA scrutiny.

Editorial Comment.

Reply by Authors.

Editorial comment. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

The great prostate cancer debate.

Recommendations on use of prostate-specific antigen for prostate cancer screening.

Ask the doctor. I take Avodart for my enlarged prostate. But I heard that Avodart increases prostate cancer risk. Is that true? Should I quit taking Avodart?

EDITORIAL COMMENT.